Filtered By:
Source: The American Journal of Cardiology

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 715 results found since Jan 2013.

High Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (From the Reasons for Geographic and Racial Differences in Stroke Study REGARDS)
The relationship between inflammation and prothrombotic state in atrial fibrillation (AF) is well recognized. This suggests a potential role for high sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation, in improving prediction of stroke in participants with AF. Cox proportional hazard analysis was used to examine the risk of stroke in 25,841 participants (40% black, 55% women) with and without AF who were enrolled in the REGARDS study between 2003 and 2007. Baseline AF (n=2,132) was ascertained by electrocardiogram and self-reported history of previous physician diagnosis.
Source: The American Journal of Cardiology - September 13, 2016 Category: Cardiology Authors: Farah Z. Dawood, Suzanne Judd, Virginia J. Howard, Nita A. Limdi, James F. Meschia, Mary Cushman, George Howard, David M. Herrington, Elsayed Z. Soliman Source Type: research

Percutaneous Coronary Intervention as a Trigger for Stroke
This study aimed to quantify the transient change in risk of stroke for up to 12 weeks after PCI. We applied the case-crossover method, using data from the Norwegian Patient Register on all hospitalizations in Norway in the period of 2008 through 2014. The relative risk (RR) of ischemic stroke was highest during the first two days after PCI (RR 17.5, 95% CI 4.2-72.8), and decreased gradually during the following weeks.
Source: The American Journal of Cardiology - September 28, 2016 Category: Cardiology Authors: Torunn Varmdal, Imre Janszky, Inger Johanne Bakken, Hanne Ellekj ær, Hild Fjærtoft, Siri Eldevik Håberg, Kaare Harald Bønaa Source Type: research

Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (From the TREAT-AF Study)
This study sought to determine the relationship between baseline stroke, bleeding risk and TTR. Using data from TREAT-AF retrospective cohort study, national Veterans Health Administration records were used to identify patients with newly diagnosed AF from 2003-2012 and subsequent initiation of warfarin.
Source: The American Journal of Cardiology - October 6, 2016 Category: Cardiology Authors: Jessica A. Hellyer, Farnaz Azarbal, Claire T. Than, Jun Fan, Susan K. Schmitt, Felix Yang, Susan M. Frayne, Ciaran S. Phibbs, Celina Yong, Paul A. Heidenreich, Mintu P. Turakhia Source Type: research

Comparison of HAS-BLED and HAS-BED versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients with Atrial Fibrillation
Anticoagulation is recommended in Atrial Fibrillation (AF) patients for stroke prevention, and the bleeding risk associated suggests the need for a bleeding risk stratification. HAS-BLED score includes ‘labile INR’ referred to quality of anticoagulation. However, in naïve patients this item is not available. In addition, stroke and bleeding risk prediction scores shared several risk factors. Aims of our study were: 1) to evaluate if the HAS-BLED score in its refined form excluding ‘labile I NR’ (HAS-BED) is still associated with bleeding risk; and 2) to evaluate the predictive ability for bleeding of both stroke a...
Source: The American Journal of Cardiology - January 24, 2017 Category: Cardiology Authors: Daniela Poli, Emilia Antonucci, Vittorio Pengo, Sophie Testa, Gualtiero Palareti Source Type: research

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (From Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial)
We investigated stroke outcomes in normal weight (body mass index [BMI] 18.50-24.99 kg/m2), overweight (BMI 25.00-29.99 kg/m2), and obese (BMI ≥30 kg/m2) patients with AF treated with rivaroxaban and warfarin. We compared the incidence of stroke and systemic embolic events (SEE) as well as bleeding events in normal weight (n=3289), overweight (n=5535), and obese (n=5206) patients in a post-hoc analysis of the ROCKET AF trial. Stroke and SEE rates per 100 patient-years were 2.93 in the normal weight group (reference group), 2.28 in the overweight group (adjusted hazard ratio [HR] 0.81, 95% confidence interval [CI]: 0.66-0...
Source: The American Journal of Cardiology - March 28, 2017 Category: Cardiology Authors: Somasekhara R. Balla, Derek D. Cyr, Yuliya Lokhyngina, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Danie Source Type: research

Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Stroke
It is unknown if closure of a patent foramen ovale (PFO) plus medical therapy (MT; antiplatelet or anticoagulation) is superior to MT alone to prevent recurrent cryptogenic stroke. We performed a meta-analysis of randomized controlled trials (RCT) that compared PFO closure plus MT to MT alone in patients with cryptogenic stroke. The efficacy endpoints were recurrent stroke, transient ischemia attack (TIA), and death. The safety endpoints were major bleeding and newly-detected atrial fibrillation (AF).
Source: The American Journal of Cardiology - December 11, 2017 Category: Cardiology Authors: Tomo Ando, Anthony A. Holmes, Mohit Pahuja, Arshad Javed, Alenxandros Briasoulis, Tesfaye Telila, Hisato Takagi, Theodore Schreiber, Luis Afonso, Cindy L. Grines, Sripal Bangalore Source Type: research

Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Cryptogenic Stroke
New evidence suggests that closure of a patent foramen ovale (PFO) plus medical therapy (MT; antiplatelet or anticoagulation) is superior to MT alone to prevent recurrent cryptogenic stroke. We performed a meta-analysis of randomized controlled trials that compared PFO closure plus MT with MT alone in patients with cryptogenic stroke. The efficacy end points were recurrent stroke, transient ischemia attack, and death. The safety end points were major bleeding and newly detected atrial fibrillation.
Source: The American Journal of Cardiology - December 11, 2017 Category: Cardiology Authors: Tomo Ando, Anthony A. Holmes, Mohit Pahuja, Arshad Javed, Alenxandros Briasoulis, Tesfaye Telila, Hisato Takagi, Theodore Schreiber, Luis Afonso, Cindy L. Grines, Sripal Bangalore Source Type: research

Meta-Analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke
The optimal management of patients with cryptogenic stroke (CS) and patent foramen ovale (PFO) remains controversial. We conducted a meta-analysis to assess the effect of PFO closure for secondary prevention of stroke in patients with CS. We searched the literature for randomized clinical trials (RCTs) assessing the recurrence of stroke after PFO closure when compared to medical therapy (antiplatelet and/or anticoagulation). Five RCTs with a total of 3440 patients were included. The mean age was 45.2 ±9.7 years and follow-up duration ranged from 2 to 5.9 years.
Source: The American Journal of Cardiology - March 2, 2018 Category: Cardiology Authors: Aiman Smer, Mohsin Salih, Toufik Mahfood Haddad, Raviteja Guddeti, Abdulghani Saadi, Alok Saurav, Ram Belbase, Mohamed Ayan, Mahmoud Traina, Venkata Alla, Michael Del Core Source Type: research

Risk of Cardioembolic Stroke in Cancer Patients with Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in cancer patients with atrial fibrillation (AF) was lower than in non-cancer patients with AF. At first glance this may appear surprising in light of the higher risk of stroke of cancer patients generally2,3, particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in cancer-free pacients.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research

Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke
The optimal management of patients with cryptogenic stroke (CS) and patent foramen ovale (PFO) remains controversial. We conducted a meta-analysis to assess the effect of PFO closure for secondary prevention of stroke on patients with CS. We searched the literature for randomized control trials assessing the recurrence of stroke after PFO closure compared with medical therapy (antiplatelet and/or anticoagulation). Five randomized control trials with a total of 3,440 patients were included. The mean age was 45.2  ± 9.7 years and follow-up duration ranged from 2.0 to 5.9 years.
Source: The American Journal of Cardiology - March 2, 2018 Category: Cardiology Authors: Aiman Smer, Mohsin Salih, Toufik Mahfood Haddad, Raviteja Guddeti, Abdulghani Saadi, Alok Saurav, Ram Belbase, Mohamed Ayan, Mahmoud Traina, Venkata Alla, Michael Del Core Source Type: research

Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in patients with cancer and atrial fibrillation (AF) was lower than in patients with AF without cancer. At first glance, this may appear surprising in light of the higher stroke risk of patients with cancer in general,2,3 particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in patients without cancer.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research

Effect of Antiplatelet Therapy (Aspirin  + Dipyridamole vs Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register (NNUHSR). The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003-2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research

Meta-Analysis Comparing The Frequency of Stroke After Transcatheter vs. Surgical Aortic Valve Replacement
Stroke is one of the most feared complication of aortic valve replacement. Although the outcomes of transcatheter aortic valve implantation (TAVI) improved substantially overtime, concerns remained about a potentially higher incidence of stroke with TAVI compared with surgical replacement (SAVR). However, comparative data are sparse. We performed a meta-analysis comparing the incidence of stroke amongst patients undergoing TAVI versus SAVR. Of the 5067 studies screened, 28 eligible studies (22 propensity-score matched studies and 6 randomized trials) were analyzed.
Source: The American Journal of Cardiology - July 5, 2018 Category: Cardiology Authors: Kuldeep Shah, Zakeih Chaker, Tatiana Busu, Vinay Badhwar, Fahad Alqahtani, Muhammad Alvi, Amelia Adcock, Mohamad Alkhouli Source Type: research

Effect of Antiplatelet Therapy (Aspirin  + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register. The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003 and 2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research